On December 5, 2022 IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, reported that it will host a conference call to discuss its quarterly results and recent business highlights for second quarter fiscal year 2023, on Thursday, December 15, 2022, at 10:30 am Eastern Time (Press release, ImmunoPrecise Antibodies, DEC 5, 2022, View Source [SID1234624766]). The financial results will be issued in a press release prior to the call.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

ImmunoPrecise management will host the conference call followed by a question-and-answer period.

Conference Call:

Date: Thursday, December 15, 2022
Time: 10:30 am Eastern time

Participant Info:

Conference ID: 9236374
Participant Toll-Free Dial-In Number: 1 (888) 550-5658
Participant Toll Dial-In Number: 1 (646) 960-0289

Attendee URL: View Source

The conference call will be webcast live and available for replay via a link provided in the Events section of the company’s IR pages at View Source

Please call the conference telephone number five minutes prior to the start time. An operator will register your name and organization.

Anyone listening to the call is encouraged to read the company’s periodic reports on file with the Toronto Stock Exchange and Securities and Exchange Commission, including the discussion of risk factors and historical results of operations and financial condition in those reports.

As previously reported, on November 23, 2022, Eterna Therapeutics Inc., a Delaware corporation (the "Company"), entered into a Securities Purchase Agreement (the "Purchase Agreement") with certain investors (the "Purchasers") providing for the private placement (the "Private Placement") to the Purchasers of an aggregate of 2,184,950 units (collectively, the "Units"), each Unit consisting of (i) one share of the Company’s common stock, par value $0.005 per share ("Common Stock") and (ii) two warrants, each exercisable to purchase one share of Common Stock (the "Warrants"), for an aggregate purchase price of approximately $7.7 million, consisting of $3.53 per Unit (inclusive of $0.125 per Warrant) (Filing, 8-K, Brooklyn ImmunoTherapeutics, DEC 5, 2022, View Source [SID1234624765]). The closing of the Private Placement occurred on December 2, 2022 (the "Closing Date").

Each Warrant has an exercise price of $3.28 per share, becomes exercisable six months following the Closing Date, expires five-and-one-half years following the Closing Date and is subject to customary adjustments. The Warrants purchased by certain of the Purchasers contain a provision pursuant to which such Warrants may not be exercised if the aggregate number of shares of Common Stock beneficially owned by the holder thereof would exceed 4.99% immediately after exercise thereof, subject to increase to 9.99% at the option of the holder.

The Company intends to use the net proceeds from the Private Placement for general working capital purposes.

Mr. Charles Cherington, Chairman of the Company’s Board of Directors, and Mr. Nicholas Singer, a director of the Company, participated in the Private Placement on the same terms and subject to the same conditions as all other Purchasers.

Pursuant to the Purchase Agreement, on the Closing Date, the Company and the Purchasers entered into a Registration Rights Agreement, pursuant to which the Company has agreed to prepare and file a registration statement on Form S-3 with the Securities and Exchange Commission no later than 30 days following the date on which the Company becomes eligible to use Form S-3 to register the resale of the shares of Common Stock included in the Units and the shares of Common Stock issuable upon exercise of the Warrants.

The foregoing description of the Warrants and the Registration Rights Agreement is only a summary and is qualified in its entirety by reference to the full text of such agreements, which are filed as Exhibits 10.1 and 10.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On December 5, 2022 Herantis Pharma Plc ("Herantis") reported that as notified earlier on December 1, 2022, it has applied for delisting of its shares from Nasdaq First North Growth Market Sweden ("Nasdaq FN GM Sweden") (Press release, Herantis Pharma, DEC 5, 2022, View Source;approved-delisting-application-regarding-the-secondary-listing-on-the-nasdaq-first-,c3677358 [SID1234624763]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nasdaq Stockholm AB approved the application December 2, 2022 and decided to delist the shares of Herantis (trading code HRNTS, ISIN code FI4000087861) from Nasdaq FN GM Sweden.

The last day of trading in the shares of Herantis on Nasdaq First North Growth Market Sweden shall be January 31, 2023.

The Company wants to remind Herantis’ shareholders holding their shares through Euroclear Sweden AB that even while the listing of Herantis’ shares on Nasdaq FN GM Sweden will be discontinued, such shareholders can continue trading in Herantis’ shares on Nasdaq First North Growth Market Finland by first arranging for the cross-border settlement of their shares into the book-entry system maintained by Euroclear Finland Oy.

Aqurat Fondkommission AB acts as Herantis’ Issuing Agent and will coordinate the conversion process:

Instructive letter will be distributed to directly registered shareholders and to all custodians
The instructive letter explains the conversion process and actions to be taken
Cross-border settlement will be done weekly

Shareholders should contact their respective custodian or Herantis Issuing Agent Aqurat Fondkommission AB ([email protected]) for more information.

On December 5, 2022 Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company, reported positive new data regarding overall survival results in its HER-Vaxx HERIZON study as provided in an oral presentation at the ESMO (Free ESMO Whitepaper) Asia Congress 2022 held in Singapore (Press release, Imugene, DEC 5, 2022, View Source [SID1234624757]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Speaking to the Congress on Sunday 4 December 2022, principal investigator Marina Maglakelidze outlined
the study design, information regarding demographics and characteristics of the 36 patients in the trial,
and data covering safety and adverse events.

Key conclusions of the overall survival benefit of HER-Vaxx included:

• HER-Vaxx + chemotherapy showed a statistically significant 42% overall survival benefit compared
to chemotherapy alone (13.9 vs 8.3 months)
• Duration of response is longer in the HER-Vaxx + chemotherapy arm over chemotherapy alone (30
vs 19 weeks)
• Vaccination with HER-Vaxx induced persistent HER-2 specific antibodies which correlated with
clinical response as proof of concept for a first-in-class B-cell immunotherapy based on HER-2
peptides
• No significant additive toxicity was seen when HER-Vaxx was administered in combination with
chemotherapy

The full presentation provided at ESMO (Free ESMO Whitepaper) can be viewed at: View Source

The oral presentation and abstract, number 74MO, was titled ‘HERIZON Overall Survival Results: A study of
IMU-131, a HER2 Targeting Peptide Vaccine, Plus Standard of Care Chemotherapy in Patients with HER2
Overexpressing Metastatic or Advanced Gastric/GEJ Cancer’.

The HERIZON study was a Phase 2 clinical trial of Imugene’s HER-Vaxx technology in Her-2/Neu
overexpressing advanced/metastatic gastric/GEJ cancer. HER-Vaxx is a B-cell activating cancer
immunotherapy designed to treat tumours that overexpress the HER-2/neu receptor, such as gastric,
breast, ovarian, lung and pancreatic cancers. The immunotherapy is constructed from several B cell
epitopes derived from the extracellular domain of HER2/neu.

On December 4, 2022 Qilu Pharmaceutical, one of the leading vertically integrated pharmaceutical companies in China that develops, manufactures, and distributes both finished formulations and Active Pharmaceutical Ingredients, reported that the results of the phase II study evaluating QL1604 plus chemotherapy as first-line treatment for patients with recurrent or metastatic (R/M) cervical cancer were released on 4 December 2022 in oral presentation (Proffered Paper, 179O) at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Asia Congress 2022 (Press release, Qilu Pharmaceutical, DEC 4, 2022, View Source [SID1234624756]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death in women worldwide. Patients with R/M cervical cancer have a poor prognosis and the 5-year survival rate is less than 20%. Although immune checkpoint inhibitors (ICIs) have shown clinical activity in R/M cervical cancer as second-line treatment, the studies on ICIs given in the first-line setting are limited.

QL1604 is a highly selective, humanized monoclonal antibody that binds to PD-1. This is a phase II, open-label, single-arm study of QL1604 plus chemotherapy in patients with R/M cervical cancer (NCT04864782). Eligible patients received QL1604 200 mg plus chemotherapy (paclitaxel and cisplatin/carboplatin) once every 3 weeks (Q3W) for up to 6 cycles, and then QL1604 200 mg Q3W for maintenance therapy until disease progression or other discontinuation events.

As of the data cutoff, 46 patients with R/M cervical cancer and naïve to systemic treatment were enrolled at 12 sites in China. Twenty (43.5%) patients previously underwent surgery and 40 (87%) patients previously received radiotherapy. Thirty-nine (84.8%) patients had recurrent disease and 7 (15.2%) patients had stage IV disease.

The median follow-up time was 12.91 months. A total of 8 (17.4%) patients achieved complete response and 19 (41.3%) patients achieved partial response, resulting in an objective response rate of 58.7% (27/46). The disease control rate was 84.8% (39/46). The median duration of response was 9.6 months (95% CI: 5.5, NE). The median progression-free survival was 8.1 months (95% CI: 5.7, 14.0). The overall survival was not reached.

QL1604 plus chemotherapy demonstrated a manageable safety profile, which was consistent with that reported for chemotherapy or anti-PD-1 therapy. The most common treatment-related adverse event was white blood cell count decreased.

Ms. Xiaoyan Kang, Head of Qilu Pharmaceutical clinical research center, stated, "We are pleased to release the latest study results of QL1604 plus chemotherapy as first-line treatment for patients with advanced cervical cancer. QL1604 plus chemotherapy showed promising antitumor activity and manageable safety profile as first-line treatment for women with R/M cervical cancer. Further investigations in this setting are ongoing.